

Quiz

DR. SONU MANUEL

CONSULTANT NEPHROLOGIST

ST. MARYS HOSPITAL

THODUPUZHA

1. True regarding evocalcet is?

A. Lower bioavailability compared with cinacalcet.

B. Similar rates of GI tract-related AEs as cinacalcet

C. fewer concerns of CYP-mediated drug interactions

D. Binds to the extracellular domain of the receptor, located on the parathyroid chief cells

Evocalcet

- Evocalcet was developed and subsequently approved in Japan in 2018 for the treatment of HD and peritoneal dialysis (PD) patients with SHPT
- It exhibits improved bioavailability compared with Cinacalcet and equivalent efficacy at a lower clinical dose.
- Lower rates of GI tract-related Aes
- Evocalcet hasfewer concerns of CYP-mediated drug interactionsand reduced off-target effects

Evocalcet ..

- evocalcet,has a naphthylethylamine structure.
- Like cinacalcet, is thought to bind to the transmembrane domain of the CaR



Comparison of calcimimetics

	Evocalcet	Cinacalcet (38)	Etelcalcetide (38)
Molecular formula	$C_{24}H_{26}N_2O_2$	$C_{22}H_{23}F_3N$	$C_{38}H_{73}N_{21}O_{10}S_2$
Molecular weight (Da)	374	394	1048
Mode of action at CaR	Allosteric modulator	Allosteric modulator	Allosteric modulator and direct agonist
Location of interaction with CaR	Transmembrane domain	Transmembrane domain	Extracellular domain
Mode of administration	Daily, oral	Daily, oral	Three times weekly, intravenously at the end of hemodialysis session


THANK
YOU